<DOC>
	<DOCNO>NCT00808145</DOCNO>
	<brief_summary>This study look safety efficacy treat advance hepatocellular carcinoma patient yet receive systemic chemotherapy . Previous local treatment hepatic lesion permit The treatment use combination three FDA approve chemotherapy drug , Gemcitabine , Cisplatin Sorafenib . Sorafenib FDA approve treatment hepatocellular cancer , gemcitabine cisplatin approve treatment hepatocellular cancer .</brief_summary>
	<brief_title>Study Sorafenib , Gemcitabine , Cisplatin Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>This study look effectiveness safety combine gemcitabine , cisplatin sorafenib treatment advance hepatocellular carcinoma patient advance disease chemo naive . Sorafenib show increase median survival tumor shrinkage RECIST criterion . Since much morbidity mortality disease occur due continue tumor growth already compromise liver , decrease size tumor might significant impact survival . The addition traditional cytoxic agent might cause measureable tumor response add survival benefit already see sorafenib . Gemcitabine cisplatin agent commonly use systemic treatment disease demonstrate effectiveness disease control rate median time progression . Gemcitabine/Cisplatin use safely combination sorafenib patient lung cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Hepatocellular carcinoma : diagnose histologically , cytologically , clinically rise AFP &gt; 500 ng/ml set cirrhosis radiographically compatible lesion . No prior systemic therapy ; local therapy chemoembolization , radiofrequency ablation cryoablation allow . Measurable disease &gt; 1 cm CT MRI . Lesions receive local therapy qualify measurable target lesion . Age &gt; 18 year old ECOG Performance Status 0 1 ChildPugh status A B Adequate bone marrow , liver renal function assess follow : Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,250/mm3 Platelet count ≥ 80,000/mm3 Total bilirubin ≤ 3.0 mg/dl ALT AST ≤ 5 time ULN Amylase lipase ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN Resolution acute toxic effect prior local treatment CTC Adverse Events grade £1 . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least three month last administration sorafenib . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR PT PTT measure prior initiation sorafenib monitor Day 1 Day 8 cycle . Prior surgery , radiation local therapy within 4 week . Prior treatment either sorafenib , gemcitabine , cisplatin Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define sustain systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection Active clinically serious infection &gt; CTCAE Grade 2 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib , cisplatin , gemcitabine . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem . Uncontrolled ascites ( define easily control diuretic treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Treatment advance liver cancer</keyword>
</DOC>